ReviewNeuropharmacology2008
Metabotropic glutamate receptors (mGlus) and cellular transformation.
Review in Neuropharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- The role of glutamate receptors in the regulation of the tumor microenvironment.Frontiers in immunology · 2023Pooled it
- In Vitro and In Vivo Studies of Melanoma Cell Migration by Antagonistic Mimetics of Adhesion Molecule L1CAM.International journal of molecular sciences · 2024Article
- GRIK3 deficiency promotes non-small cell lung cancer progression by the regulation of the UBE2C/CDK1/Wnt signaling pathway.American journal of cancer research · 2023Article
- New 1,2,4-oxadiazole derivatives with positive mGluJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer.Scientific reports · 2020Article
- Article
- Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression.Translational oncology · 2015Article
- Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor.Pigment cell & melanoma research · 2014Article
- Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.PloS one · 2014Article
- Article
- Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes.PloS one · 2013Article
- Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.International journal of biological sciences · 2013Review
- Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Effect of (S)-3,5-DHPG on microRNA expression in mouse brain.Experimental neurology · 2012Article
- Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.Breast cancer research and treatment · 2012Article
- mGlu Receptors and Cancerous Growth.Wiley interdisciplinary reviews. Membrane transport and signaling · 2012Article
- Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma.PloS one · 2012Article
- Creation of a novel peptide with enhanced nuclear localization in prostate and pancreatic cancer cell lines.BMC biotechnology · 2010Article
- The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.The Journal of investigative dermatology · 2010Article
- Ischemia-reperfusion injury of the cochlea: pharmacological strategies for cochlear protection and implications of glutamate and reactive oxygen species.Current neuropharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Although the glutamatergic system usually functions in the CNS, expression has been observed in non-neuronal tissues and a subset of cancers. Metabotropic glutamate receptors (mGlus) are highly "druggable" GPCRs and thus a priority for validation as therapeutic targets. We have previously reported that the aberrant expression of mGlu1 is sufficient to induce spontaneous melanoma development in vivo. We isolated and characterized several stable mGlu1-mouse melanocytic clones and demonstrated that these clones are transformed and tumorigenic. We hypothesize that expression of mGlus may not be uncommon in the pathogenesis of tumors other than melanoma, and that activity of an otherwise normal glutamate receptor in an ectopic cellular environment involves signaling pathways which dysregulate cell growth, ultimately leading to tumorigenesis. As most human cancers are of epithelial origin (carcinomas), in this review, the possibility that mGlu1 could function as a complete oncogene and transform epithelial cells is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.